Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis

Saudi Medical Journal

Volumn 29, Issue 5, 2008, Pages 728-733

  Tunger, Ozlem ^a   Bayram, Halim ^a   Degerli, Kenan ^a   Dinc, Gonul ^a   Cetin, Banu C ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; AMPHOTERICIN B; ECHINOCANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; INVASIVE CANDIDIASIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL RATE; TURKEY (REPUBLIC); ANIMAL; CANDIDIASIS; COMPARATIVE STUDY; DRUG COMBINATION; NONPARAMETRIC TEST;

AMPHOTERICIN B; ANIMALS; CANDIDIASIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; MICE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 50649087168     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Beck-Sague CM, Jarvis W. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infection Surveillance System. J Infect Dis 1993; 167: 1247-1251.
2. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
3. Walsh TJ, Pizzo P. Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol 1989; 7: 460-475.
4. Pappas PG, Rex JH, Sobel JD, Fillers SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
5. Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
6. Rogers TR. Antifungal drug resistance: Limited data, dramatic impact? Int J Antimicrob Agents 2006; 27 (Suppl 1): S7-S11.
7. Polak A. Combination therapy for systemic mycosis. Infection 1989; 17: 203-209.
8. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007; 30: 108-117.
9. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003; 37: 415-425.
10. Takemoto K, Yamamoto Y, Ueda Y. Evaluation of antifungal pharmacodynamic characteristics of amBisome against Candida albicans. Microbiol Immunol 2006; 50: 579-586.
11. Vonk AG, Netea MG, van Krieken JH, Verweij PE, van der Meer JW, Kullberg BJ. Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factor. Antimicrob Agents Chemother 2003; 47: 3688-3693.
12. Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 470-474.
13. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
14. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-388.
15. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
16. Clinical and Laboratory Standards Institute (CLSI). Method for broth dilution antifungal susceptibility testing for yeast. 2nd ed. Approved Standard M27-A2. Wayne (P.A): CLSI; 2002.
17. White A, Goetz MB. Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994; 19: 687-692.
18. Graybill JR, Najvar LK, Luther MF, Fothergill AW. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother 1997; 41: 1775-1777.
19. Louie A, Deziel M, Liu W, Drusano MF, GumboT, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-5068.
20. Agarwal MB, Rathi SA, Ratho N, Subramanian R. Caspofungin: A major breakthrough in treatment of systemic fungal infections. J Assoc Physicians India 2006; 54: 943-948.
21. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
22. Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother 2005; 49: 4989-4992.
23. Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-2727.
24. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51: 1427-1429.
25. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310-2318.
26. phox-/- knockout mice. Antimicrob Agents Chemother 2002; 46: 1240-1245.
27. Barchiesi F, Spreghini E, Tomassetti S, Giannini D, Scalise G. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother 2007; 51: 941-945.